1. Home
  2. PRTA vs DPG Comparison

PRTA vs DPG Comparison

Compare PRTA & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.15

Market Cap

429.2M

Sector

Health Care

ML Signal

N/A

Logo Duff & Phelps Utility and Infrastructure Fund Inc.

DPG

Duff & Phelps Utility and Infrastructure Fund Inc.

N/A

Current Price

$13.43

Market Cap

497.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
DPG
Founded
2012
N/A
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
429.2M
497.5M
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
PRTA
DPG
Price
$8.15
$13.43
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $21.40
N/A
AVG Volume (30 Days)
★ 420.1K
56.6K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $814,000.00
N/A
Revenue This Year
$775.41
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.70
$12.53
52 Week High
$11.80
$15.15

Technical Indicators

Market Signals
Indicator
PRTA
DPG
Relative Strength Index (RSI) 45.82 37.12
Support Level $8.01 $12.64
Resistance Level $9.14 $14.81
Average True Range (ATR) 0.44 0.23
MACD -0.01 -0.07
Stochastic Oscillator 37.55 9.41

Price Performance

Historical Comparison
PRTA
DPG

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.

Share on Social Networks: